Therefore,
Launch france vimkunya vaccine new: Moreover. Moreover,
Launch france vimkunya vaccine:
The Vimkunya vaccine indicated for active immunization in order to prevent the disease caused by the chikungunya virus (Chikv) among individuals aged 12. Moreover, over was launched in France on June 17, announced its Bavarian Nordic manufacturer in a statement.
VLP technology
Vimkunya obtained a European marketing authorization (AMM) on February 28. Meanwhile. Similarly, 2025 of the European Medicines Agency (EMA) after benefiting from an accelerated procedure (premium) in view of the active circulation context of the virus in certain geographic areas. Consequently. The ultramarine French territories such as the meeting are concerned in the first place but the metropolis is no longer preserved. For example, with 25 Aboriginal cases of Chikungunya identified in France on July 8, 2025. However, The chikungunya virus is today present in more than 110 countries in the world. launch france vimkunya vaccine new Nevertheless. “This vaccine is therefore intended to meet launch france vimkunya vaccine a real need for the protection of populations and travelers,” considers the laboratory.
Vimkunya is produced on a VLP platform (Virus-Like Particles, or Pseudo-Viral particles). VLPs resemble the virus in their organization. structure but are not infectious because they do not contain viral genetic material (neither DNA nor RNA). The intramuscular administration of this vaccine triggers a specific immune response neutralizing the chikungunya virus. Several vaccines based on VLP technology have been used for global immunization programs for years. successfully (papillomavirus vaccines, hepatitis B).
Unpaid
EMA’s opinion is largely based on data from two Placebo controlled studies. Study 1 assessed immunogenicity and vaccine safety in 3,258 people aged 12 to 64, and study 2 in 413 elderly people. The immune response was evaluated in 3,355 participants (2,748 with Vimkunya and 607 with placebo). The clinical launch france vimkunya vaccine new efficiency of Vimkunya has been deducted from a title of specific neutralizing launch france vimkunya vaccine antibodies. of the Chikv after vaccination. a threshold chosen as a substitution marker and called a sero-response. Eight days after vaccination. the difference in serum response rate (SRR) between vaccinated people with Vimkunya. those who received the placebo in study 1 was 46.1 %. It increased to 96 % on the 15th day, 96.6 % on the 22nd day and 84 % on the 183rd day. In study 2, the difference in SRR was 79.5 % day at day 15, 86.2 % on day 22 and 74.4 % on day 183.
Vimkunya’s safety profile is based on the grouped data of five completed clinical studies on 3,522 participants with 6 months followed. The most frequently reported side effects are fatigue, headache, muscle pain and pain at the injection point.
Unlike the IXCHIQ vaccine available launch france vimkunya vaccine new in France since the end of 2024. this non -living vaccine with pseudoviral particles can launch france vimkunya vaccine be used in anyone aged 12. over, even in the event of immunosuppression. It is not reimbursed for now (price between € 165 and € 180 including tax).
Follow Medscape in French on Bluesky , Facebook , Instagram , Linkedin , Youtube .
Register for newsletters DE MEDSCAPE: Select your choices
Further reading: “A hospital gas against Alzheimer’s”: researchers discover an unexpected effect of an anesthetic used for decades – Pregnancy: these phthalates that upset baby’s metabolism – understand symptoms and avoid bites – UV, self-tanning cabins … Can you prepare your skin for the sun? – The Helicobacter pylori bacteria could cause millions of stomach cancer cases in the years to come.
Further reading: Chikungunya: Demousticization operations in Castries after the discovery of three Aboriginal cases – Operation October pink 2025 is preparing this summer – Death in 2023: tumors, first cause of mortality – You also need it in summer! – I was diagnosed with Alzheimer’s at 41. The first sign appeared watching a film.